Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomised, Single-dose, Double-blind, Placebo-controlled, 5-way Crossover Study to Investigate the Efficacy, Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Inhaled Doses of GW642444M With and Without Magnesium Stearate in Asthmatic Patients
Brief Summary: This study will involve the use of a new medicine called GW642444 being developed for the treatment of asthma and chronic obstructive pulmonary disease (COPD). The purpose of the study is to see how safe and how well tolerated the study drug is when inhaled in two different formulations as a fine powder by asthmatic patients. In addition, the study is designed to examine the effect of the study drug on the lungs, how the study drug affects parts of the body other than the lungs and to see how the body affects the study drug when it is given in single doses.


Options:
A: Arm Label: FF/VI; Type: EXPERIMENTAL; Interventions: Drug: fluticasone furoate + vilanterol, Drug: inhaled corticosteroid with or without a long acting beta2-agonist | Arm Label: ICS or ICS/LABA maintenance therapy; Type: ACTIVE_COMPARATOR; Interventions: Drug: inhaled corticosteroid with or without a long acting beta2-agonist | Intervention Type: DRUG; Name: fluticasone furoate + vilanterol; Assigned to Arm(s): FF/VI | Intervention Type: DRUG; Name: inhaled corticosteroid with or without a long acting beta2-agonist; Assigned to Arm(s): FF/VI, ICS or ICS/LABA maintenance therapy
B: Arm Label: Fluticasone furoate/Vilanterol (GW642444); Type: EXPERIMENTAL; Interventions: Drug: Fluticasone furoate/Vilanterol Inhalation Powder, Drug: Placebo (2) | Arm Label: Fluticasone propionate/salmeterol; Type: ACTIVE_COMPARATOR; Interventions: Drug: Fluticasone propionate/salmeterol Inhalation Powder, Drug: Placebo (1) | Intervention Type: DRUG; Name: Fluticasone furoate/Vilanterol Inhalation Powder; Assigned to Arm(s): Fluticasone furoate/Vilanterol (GW642444) | Intervention Type: DRUG; Name: Fluticasone propionate/salmeterol Inhalation Powder; Assigned to Arm(s): Fluticasone propionate/salmeterol | Intervention Type: DRUG; Name: Placebo (1); Assigned to Arm(s): Fluticasone propionate/salmeterol | Intervention Type: DRUG; Name: Placebo (2); Assigned to Arm(s): Fluticasone furoate/Vilanterol (GW642444)
C: Arm Label: GW642444M/lactose; Type: EXPERIMENTAL; Interventions: Drug: Placebo, Drug: GW642444, Drug: Magnesium Stearate | Arm Label: GW642444M/MgSt; Type: EXPERIMENTAL; Interventions: Drug: Placebo, Drug: GW642444, Drug: Magnesium Stearate | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: GW642444, Drug: Magnesium Stearate | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): GW642444M/MgSt, GW642444M/lactose, Placebo | Intervention Type: DRUG; Name: GW642444; Assigned to Arm(s): GW642444M/MgSt, GW642444M/lactose, Placebo | Intervention Type: DRUG; Name: Magnesium Stearate; Assigned to Arm(s): GW642444M/MgSt, GW642444M/lactose, Placebo
D: Arm Label: GW642444M 25mcg; Type: EXPERIMENTAL; Interventions: Drug: GW642444M, Drug: placebo | Arm Label: GW642444M 50mcg; Type: EXPERIMENTAL; Interventions: Drug: GW642444M | Arm Label: GW642444M 100mcg; Type: EXPERIMENTAL; Interventions: Drug: GW642444M, Drug: placebo | Arm Label: GW642444H 100mcg; Type: EXPERIMENTAL; Interventions: Drug: GW642444H, Drug: placebo | Arm Label: placebo; Type: EXPERIMENTAL; Interventions: Drug: placebo | Intervention Type: DRUG; Name: GW642444M; Assigned to Arm(s): GW642444M 100mcg, GW642444M 25mcg, GW642444M 50mcg | Intervention Type: DRUG; Name: GW642444H; Assigned to Arm(s): GW642444H 100mcg | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): GW642444H 100mcg, GW642444M 100mcg, GW642444M 25mcg, placebo

Answer: C